Safety Study of Kudiezi (a Chinese Medicine Injection) Used in Hospitals in China
This trial is active, not recruiting.
|Conditions||coronary heart disease, angina pectoris|
|Sponsor||China Academy of Chinese Medical Sciences|
|Collaborator||Beijing University of Chinese Medicine|
|Start date||January 2012|
|End date||December 2014|
|Trial size||30000 participants|
|Trial identifier||NCT01612559, RSCMI-Ⅱ|
This study was advocated by Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences in October 2011.
It was funded by China major scientific and technological specialized project for 'significant new formulation of new drugs'.
Kudiezi is kind of Chinese Medicine injection used for treating coronary heart disease and angina pectoris in many Chinese hospitals.
The purpose of this study is to determine adverse drug events or adverse drug reaction in large sample size 30,000 patients.
Number of participants with adverse events; incidence of Kudiezi'ADRs and identify factors that contributed to the occurrence of the adverse reaction
time frame: to assess Kudiezi's 'adverse event' and 'drug adverse reaction' during patients' hospital stay, administration information of Kudiezi will be registered every day. The registry procedure will last 3 years only for patients using Kudiezi.
Male or female participants of any age.
Inclusion Criteria: - Patients using Kudiezi injection from 2012 to 2014 Exclusion Criteria: - none
|Official title||A Registry Study on Safety Surveillance of Kudiezi (a Chinese Medicine Injection) Used in China|
|Principal investigator||Yan M Xie, BA|
|Description||It is very common that Chinese Medicine Injection used in hospitals in mainland China. However safety problems rose in recent years. There could be many uncertain factors influence Chinese Medicine Injection in clinical practice. Safety surveillance on Chinese Medicine injection is an important problem that needs to be sorted out through large sample observational study. A registry study for Kudiezi injection safety surveillance with 30000 patients will be conducted from Jan.2012 to Dec.2015. Eligibility criteria Patients who will use Kudiezi injection in selected hospitals Data will be collected in four aspects by four different forms as following: Form A (blue): demographic information Form B (yellow): adverse drug events/reaction Form C (white): extracted information from hospital information system and laboratory information system Form D (red): personalized information|
Call for more information